Showing results (571-580 of 2,410) with videos related to
Sort By:
Pageof 241
Journal of Medical Economics|May 11, 2016
Cost of severe hypoglycaemia in nine European countriesMichał Jakubczyk, Izabela Lipka, Justyna Pawęska, et al.Journal of Medical Economics|June 17, 2016
Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspectiveL H Chuang, B G Verheggen, M Charokopou, et al.Journal of Medical Economics|March 1, 2019
Cost-effectiveness analyses using real-world data: an overview of the literatureKevin Bowrin, Jean-Baptiste Briere, Pierre Levy, et al.Journal of Medical Economics|May 7, 2020
The impact of frailty on the economic evaluation of geriatric surgery: hospital costs and opportunity costs based on meta-analysisFernando Fuertes-Guiró, Eduardo Viteri VelascoJournal of Medical Economics|January 19, 2024
Impact of Ebola epidemics on the daily operation of existing systems in Eastern Democratic Republic of the Congo: a brief reviewDaniel Mukadi-Bamuleka, Antoine Nkuba-Ndaye, Placide Mbala-Kingebeni, et al.Journal of Medical Economics|August 6, 2019
Ten-year Medicare budget impact of increased coverage for anti-obesity interventionFang Chen, Wenqing Su, Abhilasha Ramasamy, et al.Journal of Medical Economics|May 20, 2009
A critical review of the full economic evaluations of pharmacological treatments for colorectal cancerLivio Garattini, Paola De Compadri, Daniela Koleva, et al.Journal of Medical Economics|September 6, 2013
A systematic literature review of utility weights in wet age-related macular degenerationIsobel Pearson, Catherine Rycroft, Adam Irving, et al.Journal of Medical Economics|July 3, 2015
Cost-effectiveness analysis of exenatide twice daily (BID) vs insulin glargine once daily (QD) as add-on therapy in Chinese patients with Type 2 diabetes mellitus inadequately controlled by oral therapiesJing Deng, Shuyan Gu, Hui Shao, et al.Journal of Medical Economics|August 29, 2014
Cost of adverse events during treatment with everolimus plus exemestane or single-agent chemotherapy in patients with advanced breast cancer in Western EuropeMario Campone, Hongbo Yang, Elizabeth Faust, et al.Pageof 241